News & Updates

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

02 Dec 2023

Avacopan, when added to background induction therapy with rituximab, is as efficacious as a prednisone taper in terms of inducing remission at week 26 and is associated with a higher rate of sustained remission at week 52 in patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, according to the phase III ADVOCATE trial.

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

02 Dec 2023

Immunosuppression does not raise risk of overall, cancer mortality

01 Dec 2023

Use of immunosuppressants does not appear to increase the incidence of all-cause and cancer mortality in patients with noninfectious ocular inflammatory disease (OID) over a median follow-up of 10 years, a recent study has shown.

Immunosuppression does not raise risk of overall, cancer mortality

01 Dec 2023

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

01 Dec 2023

Previous exposure to immune checkpoint inhibitors (ICIs) does not appear to worsen COVID-19 outcomes but may even improve them in patients with cancer, according to a study.

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

01 Dec 2023

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

01 Dec 2023 by

Treatment with seladelpar significantly improves serum markers of cholestasis, including alkaline phosphatase (ALP) and total bilirubin (TB), and reduces pruritus in patients with primary biliary cholangitis (PBC) who are at risk for disease progression, according to the RESPONSE trial presented at The Liver Meeting 2023.

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

01 Dec 2023

NT-proBNP elevations during BP treatment a red flag for kidney function decline

30 Nov 2023

Higher baseline and 1-year increases in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels among individuals receiving blood pressure (BP)-lowering medications are associated with subsequent declines in estimated glomerular filtration rate (eGFR), according to a study.

NT-proBNP elevations during BP treatment a red flag for kidney function decline

30 Nov 2023

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

30 Nov 2023 by

Treatment with dupilumab reduces the use of systemic corticosteroids (SCS) in children with moderate-to-severe asthma, regardless of exacerbation history, according to a post hoc analysis of the VOYAGE and EXCURSION trials presented at APSR 2023.

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

30 Nov 2023

Elafibranor for primary biliary cholangitis scores high in phase III trial

29 Nov 2023 by

The oral, dual peroxisome proliferator-activated receptor-α/δ agonist elafibranor improves biomarkers of cholestasis and quells itching in patients with primary biliary cholangitis, while having an acceptable safety profile, as shown in the phase III ELATIVE study.

Elafibranor for primary biliary cholangitis scores high in phase III trial

29 Nov 2023

Simplified, tailored treatment for asthma improves patient outcomes

29 Nov 2023 by

Asthma is a highly prevalent disease that can affect anybody regardless of age, race, and location. The overall burden of asthma remains severe. Despite the range of available therapies and well-established guidelines, there remains a significant unmet need in the management of asthma. [BMC Public Health 2012;12:860; Respir Res 2023;24:169; Eur Respir J 2014;43:343-373]

Simplified, tailored treatment for asthma improves patient outcomes

29 Nov 2023

COVID-19 infection ups CV risk in people living with HIV

29 Nov 2023 by

People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.

COVID-19 infection ups CV risk in people living with HIV

29 Nov 2023

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

28 Nov 2023 by

Viral suppression is maintained through 48 weeks in adults with HIV-1 harbouring drug resistance mutations, who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination pill from a boosted protease inhibitor (bPI) therapy, according to recent data from the phase IV open-label PIBIK trial.

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

28 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

Immunosuppression does not raise risk of overall, cancer mortality

Immunosuppression does not raise risk of overall, cancer mortality

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

NT-proBNP elevations during BP treatment a red flag for kidney function decline

NT-proBNP elevations during BP treatment a red flag for kidney function decline

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

Elafibranor for primary biliary cholangitis scores high in phase III trial

Elafibranor for primary biliary cholangitis scores high in phase III trial

Simplified, tailored treatment for asthma improves patient outcomes

Simplified, tailored treatment for asthma improves patient outcomes

COVID-19 infection ups CV risk in people living with HIV

COVID-19 infection ups CV risk in people living with HIV

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks